Dosing and uses of Vaniqa (eflornithine cream)
Adult dosage forms and strengths
cream
- 13.9%
Reduction of Facial Hair in Women
Apply to affected area BID, 8 hours apart
Pediatric dosage forms and strengths
<12 years old: Safety & efficacy not established
Vaniqa (eflornithine cream) adverse (side) effects
Frequency not defined
Acne
Pseudofolliculitis barbae
Burning
Stinging
Dry, and/or tingling skin
Erythema
Rash
Pruritus
Alopecia
Headache
Dizziness
Dyspepsia
Warnings
Contraindications
Hypersensitivity
Pregnancy and lactation
Pregnancy category: C
Lactation: not known whether distributed into breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Vaniqa (eflornithine cream)
Absorption: <1% systemic absorption
Metabolism: none
Excretion: urine
Mechanism of action
May inhibit ornithine decarboxylase (ODC), an enzyme that catalyzes biosynthesis of intracellular polyamines required for cell division & differentiation
